Filter your results
- 3
- 3
- 3
- 2
- 1
- 3
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).BMC Medicine, 2013, 11 (1), pp.59. ⟨10.1186/1741-7015-11-59⟩
Journal articles
inserm-00817083v1
|
||
|
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.BMC Medicine, 2012, 10 (1), pp.135. ⟨10.1186/1741-7015-10-135⟩
Journal articles
inserm-00764322v1
|
||
|
Genetic variations of the A13/A14 repeat located within the EGFR 3[prime] untranslated region have no oncogenic effect in patients with colorectal cancer.BMC Cancer, 2013, 13 (1), pp.183. ⟨10.1186/1471-2407-13-183⟩
Journal articles
inserm-00813520v1
|